Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML)

Autor:	Stephen A. Strickland, Michael Chiarella, Daniel H. Ryan, Robert K. Stuart, Gary J. Schiller, Matthew J. Wieduwilt, Jorge E. Cortes, Bruno C. Medeiros, Jeffrey E. Lancet, Tara L. Lin, Donna E. Hogge, Richard Stone, Arthur C. Louie, Laura F. Newell, Geoffrey L. Uy, Jonathan E. Kolitz, Dale L. Bixby, Robert J. Ryan, Scott R. Solomon, Ellen K. Ritchie
Rok vydání:	2018
Předmět:	Oncology Cancer Research medicine.medical_specialty Chemotherapy business.industry Daunorubicin medicine.medical_treatment Newly diagnosed Internal medicine polycyclic compounds medicine Cytarabine Secondary Acute Myeloid Leukemia business medicine.drug
Zdroj:	Journal of Clinical Oncology. 36:7040-7040
ISSN:	1527-7755 0732-183X
Popis:	7040Background: CPX-351, a liposomal encapsulation of cytarabine (C) and daunorubicin (D) at a synergistic ratio, is approved in the US for treatment of adults with newly diagnosed therapy-related ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::897c8aeee15d76ba23ff2a3665f4d16c https://doi.org/10.1200/jco.2018.36.15_suppl.7040 Zobrazit plný text záznamu